{
    "clinical_study": {
        "@rank": "13239", 
        "arm_group": [
            {
                "arm_group_label": "topical menthol", 
                "arm_group_type": "Experimental", 
                "description": "topical menthol cream to hands and feet"
            }, 
            {
                "arm_group_label": "placebo cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "topical cream without menthol"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess whether six week treatment with twice a day topical Menthol application will\n      decrease persistent neuropathic pain from chemotherapy among breast and colorectal cancer\n      patients."
        }, 
        "brief_title": "Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Colon Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Peripheral Nervous System Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess whether six week treatment with BID topical Menthol application will decrease\n      persistent neuropathic pain as measured by the change in Brief Pain Inventory-Short Form\n      (BPI-SF worst pain score), following neoadjuvant/adjuvant chemotherapy with taxanes or\n      oxaliplatin-based regimens among breast and colorectal cancer patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age>21 years\n\n          2. History of stage I-III breast or colorectal cancer\n\n          3. Patient has to have completed adjuvant or neo-adjuvant Taxane based breast cancer\n             therapy or Oxaliplatin based colon cancer chemotherapy between one and 24 months\n             prior to registration\n\n          4. Signed informed consent\n\n          5. Concomitant biologic, hormonal or radiation therapy are acceptable.\n\n          6. Narcotics, antidepressants or other medications for the treatment of CIPN are\n             permitted, if patient on a stable dose for at least one month prior to enrollment.\n\n          7. Pain as defined by BPI worst pain greater than or equal to a 5 out of 10.\n\n          8. CIPN as defined  by experiencing neuropathy (numbness, tingling, thermal hyperalgesia\n             or cold allodynia) in the hands and feet frequently or most of the time in the past\n             seven days.\n\n        Exclusion Criteria:\n\n          1. Previous treatment with topical menthol (menthol/methylsalicylate products like\n             BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months\n\n          2. Known diabetic neuropathy\n\n          3. Severe concomitant illnesses\n\n          4. Known allergy or preexisting skin disease which prohibits use of menthol\n\n          5. Any topical treatment for neuropathy or other serious skin condition on the hands or\n             feet.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855607", 
            "org_study_id": "AAAL2664"
        }, 
        "intervention": [
            {
                "arm_group_label": "topical menthol", 
                "intervention_name": "topical menthol", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "placebo cream", 
                "intervention_name": "placebo cream", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Menthol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "chemotherapy induced neuropathy", 
        "lastchanged_date": "July 30, 2013", 
        "location": {
            "contact": {
                "last_name": "Man Chi Ngan", 
                "phone": "212-305-5580"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Herbert Irving Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Katherine Crew, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dawn Hershman, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial", 
        "overall_contact": {
            "email": "dlh23@columbia.edu", 
            "last_name": "Dawn L Hershman, MD", 
            "phone": "212 305-1945"
        }, 
        "overall_contact_backup": {
            "email": "mn2527@cumc.columbia.edu", 
            "last_name": "Man Chi Ngan", 
            "phone": "212 304-5580"
        }, 
        "overall_official": {
            "affiliation": "Columbia University", 
            "last_name": "Dawn Hershman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measured by BPI", 
            "measure": "neuropathic pain", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855607"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Columbia University", 
            "investigator_full_name": "Dawn L. Hershman", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "grooved pegboard and vibrometer", 
            "measure": "functional tests", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "Columbia University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Columbia University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}